Prime-boost Vaccine Study in Women With Low-grade Cervical HPV Lesions

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

108

Participants

Timeline

Start Date

March 16, 2021

Primary Completion Date

January 16, 2024

Study Completion Date

January 16, 2024

Conditions
HPV InfectionCIN1
Interventions
BIOLOGICAL

ChAdOx1-HPV

Trial vaccine

BIOLOGICAL

MVA-HPV

Trial vaccine

BIOLOGICAL

Placebo

Saline placebo vaccine

Trial Locations (16)

1070

Erasme Hospital, Brussels

1090

UZ Brussel, Brussels

2650

UZA, Antwerp

3000

UZ Leuven, Leuven

9000

UZ Gent, Ghent

10119

East-Tallinn Central Hospital, Tallinn

13419

North Estonia Medical Centre Foundation Surgery Clinic, Tallinn

51014

Tartu University Hospital Womens Clinic, Tartu

80010

Parnu Hospital Womens and Childrens Clinic, Pärnu

AB25 2ZN

Aberdeen Royal Infirmary, Aberdeen

BS2 8EG

University Hospital Bristol NHS Trust, Bristol

L8 7SS

Liverpool Women's NHS Foundation Trust, Liverpool

NE1 4LP

Royal Victoria Infirmary, Newcastle upon Tyne

NG5 1PB

Nottingham University Hospital NHS Trust, Nottingham

OX3 9DU

The University of Oxford, Nuffield Department of Women's & Reproductive Health, Oxford

PR2 9HT

Royal Preston Hospital, Preston

Sponsors
All Listed Sponsors
lead

Barinthus Biotherapeutics

INDUSTRY